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The progestogen content of combined oral
contraceptives and venous thromboembolic risk
New evidence confirms that differences exist between preparations with different progestogens
Philip C Hannaford Grampian Health Board chair of primary care
Academic Primary Care, University of Aberdeen, Aberdeen AB25 2ZD, UK
In the linked study (doi:10.1136/bmj.d6423), Lidegaard and
colleagues assess the effect of different types of combined oral
contraceptive, according to progestogen type and oestrogen
dose, on the risk of venous thromboembolism.1
Over the past four decades, more than 25 epidemiological studies
have examined the risk of venous thromboembolism in current
users of combined oral contraceptives.2All but two studies found
a significantly higher risk among current users compared with
non-users. The risk is probably greater during the first few
months of use, before falling to a level that remains above that
of non-users until the use of these contraceptives is stopped,
when the excess risk rapidly disappears. Early studies examining
the effects of the hormonal constituents tended to focus on the
oestrogen content of particular products, although one report
suggested that the progestogen content may also be important.3
Focus on the progestogen content sharpened in the mid-1990s,
when several publications reported a higher risk of venous
thromboembolism in users of combined oral contraceptives
containing the more recently introduced progestogens,
desogestrel or gestodene, compared with those using products
with the older progestogen levonorgestrel. These results,
replicated in subsequent studies, have been subjected to intense
scientific and legal scrutiny.
Recent studies reporting a higher risk—again relative to users
of levonorgestrel containing preparations—of venous
thromboembolism in users of combined oral contraceptives that
contain the latest progestogen, drospirenone, have also come
under close scrutiny. In the largest study,4 the usual trend of
declining risk after the first few months of use was absent in
women using levonorgestrel containing pills. Commentators
suggested that this might have been because of “left censoring
bias” as a result of periods of higher risk during early use being
incompletely recorded for older levonorgestrel containing pills,
unlike the newly introduced drospirenone containing products.5
Thus, the observed incidence of thrombosis in the levonorgestrel
using comparator group may have been artificially low, which
would have exaggerated the risk in drospirenone users.
Lidegaard and colleagues report findings from a four year
extension of their previous study.4 The study used four national
registries to linked data about citizenship, hospital discharge
diagnoses, deaths, and medicinal products. All Danish women
aged 15-49 years between 1995 and 2009 were identified and
those with recorded previous thrombosis, cancer, and
coagulation disturbances were excluded or censored, as were
those who were pregnant or who underwent hysterectomy,
bilateral oophorectomy, or sterilisation. First episodes of venous
thromboembolism were identified from hospital records, and
events that were treated with anticoagulants for at least four
weeks were considered confirmed (67% of all identified cases).
An independent assessment of 200 cases indicated that venous
thromboembolism was confirmed in most women given
anticoagulation. The authors calculated person time exposure
to hormonal contraception using information from the national
registry of medicinal products about hormonal contraceptive
prescriptions redeemed between 1995 and 2009. Although the
study focused on the period after the launch of drospirenone
containing combined oral contraceptives in Denmark (2001-9),
prescription data from 1995 were used for the calculation of
duration of hormonal contraceptive use. This greatly reduced
the potential for left censoring bias. Sensitivity analyses tested
assumptions made in the construction of periods of exposure,
with generally few differences between results.
During the eight million women years of observation, 4246 first
episodes of venous thromboembolism occurred. Among the
confirmed cases, and after adjustment for age, calendar year,
education, and length of use, the relative risk of venous
thromboembolic risk in women who used pills with desogestrel,
gestodene, or drospirenone was twice that of those who used
pills with levonorgestrel. The estimated average absolute risk
in current users of newer pills was about 10 per 10 000 women
years. Although the corresponding relative risks in
non-confirmed cases tended to be smaller, those for combined
oral contraceptives containing gestodene or drospirenone were
still significantly greater than for those containing
levonorgestrel. Preparations with a newer progestogen and 20
µg of oestrogen did not have a significantly lower risk of venous
thrombosis than those with the same progestogen and 30 µg of
oestrogen. Progestogen only oral contraceptives and the
p.hannaford@abdn.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d6592 doi: 10.1136/bmj.d6592 Page 1 of 2
Editorials
EDITORIALS
levonorgestrel releasing intrauterine device were not associated
with an increased risk of venous thromboembolism.
A key concern with any data linkage study is the quality of
information collected, often recorded during everyday practice
in an unstructured way. A crucial consideration is whether there
is likely to be differential recording of information among the
various exposure groups, and if so, whether this is related to
outcome. There is little reason to suspect that this occurred in
this study. Furthermore, the similar proportion of confirmed
cases in the different groups argues against differential referral
or diagnostic bias as an explanation for the study’s results.
Information about important potential confounders—such as
body mass index and family history of venous
thromboembolism—is often absent, incomplete, or out of date
in routine datasets. Residual confounding should therefore
always be considered in the assessment of results from data
linkage studies. Such effects, however, would have to be large
to account for a doubling of risk.
This new study has tackled many of the concerns expressed
about the earlier investigation. Although unpalatable to some,
it is difficult not to conclude that combined oral contraceptives
with desogestrel, gestodene, or drospirenone confer a higher
risk of venous thromboembolism than those with levonorgestrel.
Many clinicians will choose to minimise the risk by prescribing
a combined oral contraceptive with levonorgestrel whenever
possible. It is crucial, however, not to exaggerate the risk—oral
contraceptives are remarkably safe and may confer important
long term benefits in relation to cancer and mortality.6 7
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